The following is a summary of “Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving ...

The positive trial results could help Regeneron cushion the blow of its disappointing fourth-quarter sales for Eylea, which exceeded the consensus by a modest 1% and are bogged down by the slow ...

Regeneron shares have been in a bearish trend since August, losing over one third of their value. Read why I am initiating REGN stock with a buy rating.

Cemiplimab significantly reduced the risk of recurrence or death in patients with high-risk cutaneous squamous cell carcinoma ...

Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial: Tarrytown, New York Wednesday, January 15, 2025, 11:00 Hrs [IST] ...